Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  AB Science    AB   FR0010557264

AB SCIENCE

(AB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The share is getting closer to its long-term support in weekly data, at EUR 9.04, which offers good timing for buyers.
  • The group usually releases upbeat results with huge surprise rates.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 9.04 EUR
Weaknesses

No significant weakness

Ratings chart
Sector Specialty & Advanced Pharmaceuticals
1st jan.Capitalisation (M$)Investor Rating
AB SCIENCE89.59%555
-
MERCK KGAA28.33%71 018
ZHANGZHOU PIENTZEHUANG PHAR..103.99%20 446
KYOWA KIRIN CO., LTD.11.39%14 808
BETTA PHARMACEUTICALS CO., ..47.90%5 673
YUHAN CORPORATION38.48%3 515
RECIPHARM AB (PUBL)32.26%2 057
SUPERNUS PHARMACEUTICALS, I..-8.26%1 142
INDIVIOR158.97%988
KISSEI PHARMACEUTICAL CO., ..-32.40%960
CALLIDITAS THERAPEUTICS AB ..94.19%863
DONG-A ST CO., LTD.-27.31%664
NICHI-IKO PHARMACEUTICAL CO..-26.01%615
KNIGHT THERAPEUTICS INC.-29.42%542
CHONG KUN DANG HOLDINGS COR..7.43%493
MAYNE PHARMA GROUP LIMITED-19.54%440
More Results
Financials
Sales 2020 1,80 M 2,19 M 2,19 M
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 457 M 555 M 556 M
Capi. / Sales 2020 254x
Capi. / Sales 2021 229x
Nbr of Employees 93
Free-Float 55,3%
Upcoming event on AB SCIENCE
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating -
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability -
P/E ratio -
Potential
Yield -
Consensus -
7 days EPS revision -
4 months EPS revision -
1 year EPS revision -
4 months Revenue revision -
1 year Revenue revision -
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes